Thomas J Coates1, Michal Kulich2, David D Celentano3, Carla E Zelaya3, Suwat Chariyalertsak4, Alfred Chingono5, Glenda Gray6, Jessie K K Mbwambo7, Stephen F Morin8, Linda Richter9, Michael Sweat10, Heidi van Rooyen11, Nuala McGrath12, Agnès Fiamma13, Oliver Laeyendecker14, Estelle Piwowar-Manning15, Greg Szekeres13, Deborah Donnell16, Susan H Eshleman15. 1. University of California, Los Angeles, UCLA Center for World Health, Los Angeles, CA, USA. Electronic address: tcoates@mednet.ucla.edu. 2. Charles University, Faculty of Mathematics and Physics, Prague, Czech Republic. 3. Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD, USA. 4. Chiang Mai University, Research Institute for Health Sciences, Chiang Mai, Thailand. 5. University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe. 6. University of the Witwatersrand, Chris Hani Baragwanath Hospital, Faculty of Health Sciences, Perinatal HIV Research Unit, Soweto, South Africa. 7. Muhimbili University of Health and Allied Sciences, Muhimbili University Teaching Hospital, Dar es Salaam, Tanzania. 8. University of California, San Francisco, Center for AIDS Prevention Studies, San Francisco, CA, USA. 9. Human Sciences Research Council, Dalbridge, South Africa. 10. Medical University of South Carolina, Family Services Research Center, Charleston, SC, USA. 11. Human Sciences Research Council, Durban, South Africa. 12. University of Southampton, Southampton General Hospital, Southampton, UK. 13. University of California, Los Angeles, UCLA Center for World Health, Los Angeles, CA, USA. 14. Johns Hopkins University School of Medicine, Department of Medicine, Baltimore, MD, USA; The National Institutes of Health, Bethesda, MD, USA. 15. Department of Pathology, Baltimore, MD, USA. 16. Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Abstract
BACKGROUND: Although several interventions have shown reduced HIV incidence in clinical trials, the community-level effect of effective interventions on the epidemic when scaled up is unknown. We investigated whether a multicomponent, multilevel social and behavioural prevention strategy could reduce HIV incidence, increase HIV testing, reduce HIV risk behaviour, and change social and behavioural norms. METHODS: For this phase 3 cluster-randomised controlled trial, 34 communities in four sites in Africa and 14 communities in Thailand were randomly allocated in matched pairs to receive 36 months of community-based voluntary counselling and testing for HIV (intervention group) or standard counselling and testing alone (control group) between January, 2001, and December, 2011. The intervention was designed to make testing more accessible in communities, engage communities through outreach, and provide support services after testing. Randomisation was done by a computer-generated code and was not masked. Data were collected at baseline (n=14 567) and after intervention (n=56.683) by cross-sectional random surveys of community residents aged 18-32 years. The primary outcome was HIV incidence and was estimated with a cross-sectional multi-assay algorithm and antiretroviral drug screening assay. Thailand was excluded from incidence analyses because of low HIV prevalence. This trial is registered at ClinicalTrials.gov, number NCT00203749. FINDINGS: The estimated incidence of HIV in the intervention group was 1.52% versus 1.81% in the control group with an estimated reduction in HIV incidence of 13.9% (relative risk [RR] 0.86, 95% CI 0.73-1.02; p=0.082). HIV incidence was significantly reduced in women older than 24 years (RR=0.70, 0.54-0.90; p=0.0085), but not in other age or sex subgroups. Community-based voluntary counselling and testing increased testing rates by 25% overall (12-39; p=0.0003), by 45% (25-69; p<0·0001) in men and 15% (3-28; p=0.013) in women. No overall effect on sexual risk behaviour was recorded. Social norms regarding HIV testing were improved by 6% (95% CI 3-9) in communities in the intervention group. INTERPRETATION: These results are sufficiently robust, especially when taking into consideration the combined results of modest reductions in HIV incidence combined with increases in HIV testing and reductions in HIV risk behaviour, to recommend the Project Accept approach as an integral part of all interventions (including treatment as prevention) to reduce HIV transmission at the community level. FUNDING: US National Institute of Mental Health, the Division of AIDS of the US National Institute of Allergy and Infectious Diseases, and the Office of AIDS Research of the US National Institutes of Health.
RCT Entities:
BACKGROUND: Although several interventions have shown reduced HIV incidence in clinical trials, the community-level effect of effective interventions on the epidemic when scaled up is unknown. We investigated whether a multicomponent, multilevel social and behavioural prevention strategy could reduce HIV incidence, increase HIV testing, reduce HIV risk behaviour, and change social and behavioural norms. METHODS: For this phase 3 cluster-randomised controlled trial, 34 communities in four sites in Africa and 14 communities in Thailand were randomly allocated in matched pairs to receive 36 months of community-based voluntary counselling and testing for HIV (intervention group) or standard counselling and testing alone (control group) between January, 2001, and December, 2011. The intervention was designed to make testing more accessible in communities, engage communities through outreach, and provide support services after testing. Randomisation was done by a computer-generated code and was not masked. Data were collected at baseline (n=14 567) and after intervention (n=56.683) by cross-sectional random surveys of community residents aged 18-32 years. The primary outcome was HIV incidence and was estimated with a cross-sectional multi-assay algorithm and antiretroviral drug screening assay. Thailand was excluded from incidence analyses because of low HIV prevalence. This trial is registered at ClinicalTrials.gov, number NCT00203749. FINDINGS: The estimated incidence of HIV in the intervention group was 1.52% versus 1.81% in the control group with an estimated reduction in HIV incidence of 13.9% (relative risk [RR] 0.86, 95% CI 0.73-1.02; p=0.082). HIV incidence was significantly reduced in women older than 24 years (RR=0.70, 0.54-0.90; p=0.0085), but not in other age or sex subgroups. Community-based voluntary counselling and testing increased testing rates by 25% overall (12-39; p=0.0003), by 45% (25-69; p<0·0001) in men and 15% (3-28; p=0.013) in women. No overall effect on sexual risk behaviour was recorded. Social norms regarding HIV testing were improved by 6% (95% CI 3-9) in communities in the intervention group. INTERPRETATION: These results are sufficiently robust, especially when taking into consideration the combined results of modest reductions in HIV incidence combined with increases in HIV testing and reductions in HIV risk behaviour, to recommend the Project Accept approach as an integral part of all interventions (including treatment as prevention) to reduce HIV transmission at the community level. FUNDING: US National Institute of Mental Health, the Division of AIDS of the US National Institute of Allergy and Infectious Diseases, and the Office of AIDS Research of the US National Institutes of Health.
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Becky L Genberg; Zdenek Hlavka; Kelika A Konda; Suzanne Maman; Suwat Chariyalertsak; Alfred Chingono; Jessie Mbwambo; Precious Modiba; Heidi Van Rooyen; David D Celentano Journal: Soc Sci Med Date: 2009-05-07 Impact factor: 4.634
Authors: Gertrude Khumalo-Sakutukwa; Stephen F Morin; Katherine Fritz; Edwin D Charlebois; Heidi van Rooyen; Alfred Chingono; Precious Modiba; Khalifa Mrumbi; Surasing Visrutaratna; Basant Singh; Michael Sweat; David D Celentano; Thomas J Coates Journal: J Acquir Immune Defic Syndr Date: 2008-12-01 Impact factor: 3.731
Authors: Sebastian Kevany; Gertrude Khumalo-Sakutukwa; Oliver Murima; Alfred Chingono; Precious Modiba; Glenda Gray; Heidi Van Rooyen; Khalifa Mrumbi; Jessie Mbwambo; Surinda Kawichai; Suwat Chariyalertsak; Chonlisa Chariyalertsak; Elizabeth Paradza; Marta Mulawa; Kathryn Curran; Katherine Fritz; Stephen F Morin Journal: BMC Public Health Date: 2012-06-20 Impact factor: 3.295
Authors: Oliver Laeyendecker; Estelle Piwowar-Manning; Agnes Fiamma; Michal Kulich; Deborah Donnell; Deb Bassuk; Caroline E Mullis; Craig Chin; Priscilla Swanson; John Hackett; William Clarke; Mark Marzinke; Greg Szekeres; Glenda Gray; Linda Richter; Michel W Alexandre; Suwat Chariyalertsak; Alfred Chingono; David D Celentano; Stephen F Morin; Michael Sweat; Thomas Coates; Susan H Eshleman Journal: PLoS One Date: 2013-07-11 Impact factor: 3.240
Authors: Oliver Laeyendecker; Michal Kulich; Deborah Donnell; Arnošt Komárek; Marek Omelka; Caroline E Mullis; Greg Szekeres; Estelle Piwowar-Manning; Agnes Fiamma; Ronald H Gray; Tom Lutalo; Charles S Morrison; Robert A Salata; Tsungai Chipato; Connie Celum; Erin M Kahle; Taha E Taha; Newton I Kumwenda; Quarraisha Abdool Karim; Vivek Naranbhai; Jairam R Lingappa; Michael D Sweat; Thomas Coates; Susan H Eshleman Journal: PLoS One Date: 2013-11-13 Impact factor: 3.240
Authors: Jessica M Fogel; Estelle Piwowar-Manning; Kelsey Donohue; Vanessa Cummings; Mark A Marzinke; William Clarke; Autumn Breaud; Agnès Fiamma; Deborah Donnell; Michal Kulich; Jessie K K Mbwambo; Linda Richter; Glenda Gray; Michael Sweat; Thomas J Coates; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: Echezona E Ezeanolue; Michael C Obiefune; Chinenye O Ezeanolue; John E Ehiri; Alice Osuji; Amaka G Ogidi; Aaron T Hunt; Dina Patel; Wei Yang; Jennifer Pharr; Gbenga Ogedegbe Journal: Lancet Glob Health Date: 2015-11 Impact factor: 26.763
Authors: Ethan Klock; George Mwinnya; Leigh Anne Eller; Reinaldo E Fernandez; Hannah Kibuuka; Sorachai Nitayaphan; Josphat Kosgei; Richard D Moore; Merlin Robb; Susan H Eshleman; Oliver Laeyendecker Journal: AIDS Res Hum Retroviruses Date: 2020-05-27 Impact factor: 2.205